Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720624 | 1.00 | LSS (0.46) | LSSCHRNA7BCHEACHEGLA | |
| SCHEMBL1724185 | 0.82 | CHRNA7 (0.62) | CHRNA7BCHEACHECHRM2CHRM1 | |
| SCHEMBL9469447 | 0.81 | LSS (0.55) | LSSCHRNA7 | |
| SCHEMBL373165 | 0.80 | CHRNA7 (0.70) | CHRNA7BCHEACHECHRM2CHRM1 | |
| SCHEMBL1721045 | 0.79 | MEN1 (0.58) | LSSCHRNA7BCHEACHEGLA | |
| SCHEMBL1720506 | 0.79 | MEN1 (0.58) | LSSCHRNA7BCHEACHEGLA | |
| SCHEMBL3743481 | 0.73 | CHRM2 (0.71) | CHRNA7BCHEACHEGLACHRM2 | |
| SCHEMBL228826 | 0.72 | CHRM3 (0.65) | CHRNA7BCHEACHECHRM2CHRM1 | |
| SCHEMBL228827 | 0.72 | CHRM3 (0.65) | CHRNA7BCHEACHECHRM2CHRM1 | |
| SCHEMBL1355778 | 0.72 | PARP15 (0.53) | MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2011-12-29 | — | — | US | claimed |
| EP-2406257-B1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA P LTD (IN) | 2019-08-07 | — | — | EP | disclosed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | disclosed |
| EP-2406257-A1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | Megafine Pharma (P) Ltd. (IN) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103529-A1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | CHRM3, CHRNA1, ADRA1A | LSS 3082/4885CHRNA7 21/4885BCHE 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.